Literature DB >> 19701234

An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study.

Gan Zhou1, Zhi-rong Tan, Wei Zhang, Dong-sheng Ou-Yang, Yao Chen, Dong Guo, Ying-zi Liu, Lan Fan, Han-wu Deng.   

Abstract

AIM: To improve and validate an analytical method based on liquid chromatography and electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) for the quantitative measurement of ilaprazole and its two metablites in human plasma.
METHODS: Separation of analytes and the internal standard (IS), omeprazole, was performed on a Thermo HyPURITY C18 column (150x2.1 mm, 5 microm) with a mobile phase consisting of 10 mmol/L ammonium formate water-acetonitrile solution (50:50, v/v) at a flow rate of 0.25 mL/min. The API4000 triple quadruple mass spectrometer was operated in multiple reactions monitoring mode via positive electrospray ionization interface using the transition m/z 367.2 --> m/z184.0 for ilaprazole, m/z 383.3 --> m/z 184.1 for ilaprazole sulfone, m/z 351.2 --> m/z 168.1 for ilaprazole thiol ether and m/z 346.2 --> m/z 198.0 for omeprazole.
RESULTS: The method was linear over the concentration range of 0.23-2400.00 ng/mL for ilaprazole, 0.05-105.00 ng/mL for ilaprazole thiol ether and 0.06-45.00 ng/mL for ilaprazole sulfone. The intra- and inter-day precisions were all less than 15% in terms of relative standard deviation (RSD), and the accuracy was within 15% in terms of relative error (RE) for ilaprazole, ilaprazole sulfone and ilaprazole thiol ether. The lower limit of quantification (LLOQ) was identifiable and reproducible at 0.23, 0.05 and 0.06 ng/mL with acceptable precision and accuracy for ilaprazole, ilaprazole sulfone and ilaprazole thiol ether, respectively.
CONCLUSION: The validated method offered sensitivity and a wide linear concentration range. This method was successfully applied for the evaluation of the pharmacokinetics of ilaprazole and its two metabolites after single oral doses of 5 mg ilaprazole to 12 healthy Chinese volunteers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701234      PMCID: PMC4007177          DOI: 10.1038/aps.2009.120

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  7 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry.

Authors:  S W Myung; H K Min; C Jin; M Kim; S M Lee; G J Chung; S J Park; D Y Kim; H W Cho
Journal:  Arch Pharm Res       Date:  1999-04       Impact factor: 4.946

3.  A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.

Authors:  A P Periclou; R Goldwater; S M Lee; D W Park; D Y Kim; K D Cho; F Boileau; W T Jung
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

Review 4.  Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry.

Authors:  Paul J Taylor
Journal:  Clin Biochem       Date:  2005-04       Impact factor: 3.281

5.  Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.

Authors:  Yalin Li; Wei Zhang; Dong Guo; Gan Zhou; Honghao Zhou; Zhousheng Xiao
Journal:  Clin Chim Acta       Date:  2008-02-14       Impact factor: 3.786

6.  Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis.

Authors:  H T Karnes; C March
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

7.  General pharmacology of IY-81149, a new proton pump inhibitor.

Authors:  E J Kim; R K Lee; S M Lee; D Y Kim
Journal:  Arzneimittelforschung       Date:  2001-01
  7 in total
  3 in total

1.  Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy.

Authors:  Shan Cao; Gan Zhou; Dong-sheng Ou-Yang; Hui-zi Wu; Kui Xiao; Yao Chen; Dong Guo; Lan Fan; Zhi-rong Tan; Hai-tang Hu; Xiang-hong Qin; Hong-hao Zhou; Wei Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-07-23       Impact factor: 6.150

2.  Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study.

Authors:  Byung Hak Jin; Byung Won Yoo; Jungsin Park; Jung Hye Kim; Jun Yeon Lee; Jae Soo Shin; Min Soo Park
Journal:  Eur J Clin Pharmacol       Date:  2018-05-30       Impact factor: 2.953

3.  Identification of the New In Vivo Metabolites of Ilaprazole in Rat Plasma after Oral Administration by LC-MS: In Silico Prediction of the H+/K+-ATPase Inhibitor.

Authors:  Guiqiu Zhang; Kaijing Guo; Pengfei Wang; Yingbo Shan; Chen Ma
Journal:  Molecules       Date:  2021-01-16       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.